Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Feb;14(2):208-23.
doi: 10.1016/S1474-4422(14)70264-9.

Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives

Daniel Ontaneda  1 , Robert J Fox  2 , Jeremy Chataway  3
Affiliations
Review

Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives

Daniel Ontaneda et al. Lancet Neurol. 2015 Feb.

Abstract

Progressive multiple sclerosis is characterised clinically by the gradual accrual of disability independent of relapses and can occur with disease onset (primary progressive) or can be preceded by a relapsing disease course (secondary progressive). An effective disease-modifying treatment for progressive multiple sclerosis has not yet been identified, and so far the results of clinical trials have generally been disappointing. Ongoing advances in the knowledge of pathogenesis, in the identification of novel targets for neuroprotection, and in improved outcome measures could lead to effective treatments for progressive multiple sclerosis. In this Series paper, we summarise the lessons learned from completed clinical trials and perspectives from trials in progress in progressive multiple sclerosis. We review promising clinical, imaging, and biological markers, along with novel designs, for clinical trials. The use of more refined outcomes and truly neuroprotective drugs, coupled with more efficient trial design, has the capacity to deliver a new era of therapeutic discovery in this challenging area.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 2
Figure 2
See this image and copyright information in PMC

References

    1. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology. 2014;83(3):278–286. - PMC - PubMed
    1. Trapp BD, Nave KA. Multiple sclerosis: An immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–269. - PubMed
    1. Miller AE, Rhoades RW. Treatment of relapsing-remitting multiple sclerosis: Current approaches and unmet needs. Curr Opin Neurol. 2012;25 (Suppl):S4–10. - PubMed
    1. Wiendl H, Hohlfeld R. Multiple sclerosis therapeutics: Unexpected outcomes clouding undisputed successes. Neurology. 2009;72(11):1008–1015. - PubMed
    1. British And Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. british and dutch multiple sclerosis azathioprine trial group. Lancet. 1988;2(8604):179–183. - PubMed

Publication types

MeSH terms